Palonosetron (INN, trade name Aloxi) is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINVÂ-nausea and vomiting and there are tentative data to suggest that it may be better than granisetron. Palonosetron is administered intravenously, as a single dose, 30 minutes before chemotherapy, or as a single oral capsule one hour before chemotherapy. The oral formulation was approved on August 22, 2008 for prevention of acute CINV alone, as a large clinical trial did not show oral administration to be as effective as intravenous use against delayed CINV.
Palonosetron Hcl is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).
Properties:
Appearance & Physical State: White Solid
Melting Point: >290ºC
Boiling Point: 470.4ºC at 760 mmHg
Flash Point: 209.5ºC
Vapor Pressure: 5.07E-09mmHg at 25°C
5-HT Receptor Inhibitors Related Products:
Iloperidone; Olanzapine; Clozapine; Agomelatine; Duloxetine hydrochloride; Duloxetine; Alosetron hydrochloride; Lurasidone; Lurasidone hydrochloride; Ramosetron Hydrochloride; Atomoxetine hcl